昭衍助力2025年9月25日,益科思特(北京)医药科技发展有限公司(下称“益科思特”)自主研发的靶向CD19/CD3的创新双特异性抗体YK012.正式获得美国食品药品监督管理局(FDA)的临床试验批准(IND),用于治疗原发性膜性肾病(pMN)。这是全球首个针对该适应症获批临床的T细胞衔接器(TCE)类双抗药物,标志着中国原研双抗技术在自身免疫病领域实现中美同步突破。昭衍新药作为益科思特的非临床...
Source Link昭衍助力2025年9月25日,益科思特(北京)医药科技发展有限公司(下称“益科思特”)自主研发的靶向CD19/CD3的创新双特异性抗体YK012.正式获得美国食品药品监督管理局(FDA)的临床试验批准(IND),用于治疗原发性膜性肾病(pMN)。这是全球首个针对该适应症获批临床的T细胞衔接器(TCE)类双抗药物,标志着中国原研双抗技术在自身免疫病领域实现中美同步突破。昭衍新药作为益科思特的非临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.